Patent directory · USPTO A61K / A61P
Patents matching “REGENERON PHARMACEUTICALS, INC.”
837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 10562953
GPR156 variants and uses thereof
granted -
US 10561126
Genetically modified non-human animals and methods of use thereof
granted -
US 10550192
Antigen-binding proteins that antagonize leptin receptor
granted -
US 10548302
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
granted -
US 10550193
Methods and antibody compositions for tumor treatment
granted -
US 10544232
Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
granted -
US 10532096
Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody
granted -
US 10524458
Humanized C3 animals
granted -
US 10526344
Amino acid acylation reagents and methods of using the same
granted -
US 10526403
Anti-activin A antibodies and uses thereof
granted -
US 10525106
Angiopoietin-based interventions for treating cerebral malaria
granted -
US 10525104
Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
granted -
US 10519240
Anti-FGFR1c antibody-FGF21 fusion proteins
granted -
US 10519230
Nucleic acids encoding IL-33 antibodies
granted -
US 10513557
Anti-ASIC1 antibodies and uses thereof
granted -
US 10501526
Human antibodies to Ebola virus glycoprotein
granted -
US 10492477
Humanized C5 animals
granted -
US 10494442
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
granted -
US 10485844
Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
granted -
US 10472425
Stabilized formulations containing anti-PCSK9 antibodies
granted -
US 10464992
VEGF antagonist formulations suitable for intravitreal administration
granted -
US 10463749
Maytansinoid derivatives, conjugates thereof, and methods of use
granted -
US 10463028
Genetically modified non-human animals expressing human EPO
granted -
US 10463029
Rodent model of steel syndrome
granted